Almirall SA: A Strong Start to 2025 with Impressive Q1 Results

In a promising start to 2025, Almirall SA, a leading pharmaceutical company headquartered in Barcelona, Spain, has reported robust first-quarter results. The company, known for its strategic brands such as ACTIKERALL, BALNEUM, and SATIVEX, has demonstrated significant growth, particularly in its European Dermatology business.

Q1 Performance Highlights

Almirall’s overall sales surged by 15% year-over-year, reaching €284.6 million. This growth is a testament to the company’s sustained trajectory and strategic initiatives. The European Dermatology segment outperformed with a remarkable 23.4% increase, underscoring the strength of Almirall’s product portfolio in this area.

The company’s EBITDA also saw a substantial rise of 35.0% year-over-year, amounting to €70.9 million. This increase aligns with expectations and reflects Almirall’s strong operational execution. A notable contributor to this performance was the out-licensing transaction in Q1 2025, which bolstered the general medicines business.

Key Product Performances

Almirall’s biologics portfolio played a pivotal role in driving growth. Ilumetri®, a key product, experienced a 12.7% increase in sales compared to Q1 2024, totaling €55.1 million. Ebglyss® also performed well, achieving €19.4 million in quarterly sales. This success was largely due to positive launch dynamics in Germany and expanding contributions from recently launched countries.

The company’s broad dermatology product portfolio continued to exhibit sustained growth, meeting expectations and reinforcing Almirall’s position in the market.

Upcoming Events

In light of these results, Almirall has announced a conference to introduce and explain the first quarter 2025 results. The event will be webcast, allowing stakeholders to gain insights into the company’s performance and strategic direction. Additionally, Almirall has filed the presentation for its first-quarter results, ensuring transparency and accessibility for investors and analysts.

Strategic Outlook

As Almirall continues to build on its strong foundation, the company remains focused on innovation and growth. With a market capitalization of €2.08 billion and a price-to-earnings ratio of 200, Almirall is well-positioned to capitalize on opportunities in the healthcare sector. The company’s commitment to research, development, and strategic partnerships will be crucial in maintaining its competitive edge.

For more information, stakeholders can visit Almirall’s website at www.almirall.com or follow updates on the Bolsa De Madrid stock exchange, where the company is listed.